A nurse is caring for a client who has diabetes mellitus and is taking pioglitazone. The nurse should plan to monitor the client for which of the following adverse effects?

Simvastatin is an HMG-CoA reductase inhibitorused to treat dyslipidemia by reducing hepatic cholesterol synthesis. While effective for cardiovascular prophylaxis, it carries risks of hepatotoxicityand myopathy. Clinical monitoring focuses on liver function tests and markers of muscle integrity to detect early signs of statin-inducedorgan injury.

Rationale:

A.Decreased creatine kinase (CK) is not a finding of clinical concern; however, increased CK would be highly significant. Elevated CK levels indicate muscle breakdown or rhabdomyolysis, which is a rare but severe side effect of statin therapy. A low or normal CK level suggests that the medication is not currently causing significant damage to the client's skeletal muscle tissue.

B.Increased alkaline phosphatase is a marker of potential liver injury or biliary obstruction and must be reported to the provider immediately. Since simvastatin is processed by the liver, it can cause asymptomatic elevations in liver enzymes or, in rare cases, drug-induced hepatitis. The nurse must monitor for jaundice and upper quadrant pain when these laboratory values are elevated.

C.Increased HDL is a positive therapeutic outcome of simvastatin therapy and does not need to be reported as an adverse finding. High-density lipoprotein is the "good" cholesterol that aids in the transport of cholesterol away from the arteries. An increase in this value indicates that the medication and lifestyle changes are successfully reducing the client's overall cardiovascular risk profile.

D.Decreased HbA1c is generally a favorable finding, as it indicates improved long-term glucose control. Statins have actually been associated with a slight increase in HbA1c and blood glucose levels in some patients, potentially increasing the risk of diabetes. Therefore, a decrease would not be considered a medication-related adverse effect that requires urgent notification to the healthcare provider.

Digoxin is a cardiac glycosidethat inhibits the sodium-potassium ATPasepump, increasing intracellular calcium and myocardial contractility. It possesses a narrow therapeutic index, making toxic accumulations common. Early toxicity manifests as anorexia, nausea, and blurred or yellow-tinted vision, while severe toxicity causes life-threatening dysrhythmias.

Rationale:

A.Notifying the provider is a necessary step in the management of a medication error, but it is not the initial action. The nurse must first possess objective clinical data regarding the client's current physiological status to provide a comprehensive report. Assessment always precedes notification in the nursing process to ensure the provider can make informed decisions.

B.Obtaining the client's vital signs is the priority action because the nurse must assess for immediate life-threatening complications like severe bradycardia or hypotension. Since digoxin significantly affects cardiac conduction, an overdose can trigger various arrhythmias. Assessing the client's stability provides the essential data needed to determine the urgency of further medical interventions.

C.Initiating a medication error incident report is an administrative requirement that ensures institutional quality improvement and safety tracking. However, documentation is never the first priority when a client's safety is potentially compromised by a pharmacological overdose. The nurse must focus on clinical assessment and stabilization before completing necessary internal paperwork regarding the error.

D.Checking the client's digoxin level is an important diagnostic step to quantify the severity of the overdose, but it takes time to process. Laboratory results do not provide immediate information about the client's current hemodynamic tolerance of the excess dose. The nurse should prioritize the physical assessment of the client over waiting for laboratory confirmation of serum levels.